

Amended claims

1. Use of a fatty acid composition comprising (all-Z
omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or
5 derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-
docosahexaenoic acid (DHA), or derivatives thereof, or
any combinations thereof, for the production of a
medicinal product for controlling body weight reduction,
for preventing body weight gain and for treatment and/or
10 prevention of obesity or an overweight condition, wherein
the weight ratio of EPA:DHA in the fatty acid composition
is 1:X, where X is equal or greater than 1.
2. Use according to claim 1, wherein the combination of
15 EPA and DHA are present in the composition in an EPA:DHA
ratio from 1:1 to 1:8, preferably in an EPA:DHA ratio
from 1:1 to 1:6.
3. Use according to claim 1, wherein the fatty acids in
20 the composition is presented in at least one of
esterified form, ethyl ester form, salt form and free
acid form, or any combinations thereof.
4. Use according to claim 1, wherein at least one of EPA
25 and DHA is obtained from at least one of vegetable,
microbial and animal origins or combinations thereof.
5. Use according to claim 1, wherein at least a part of
the EPA and/or DHA is produced from a marine oil,
30 preferably a fish oil.

AMENDED SHEET

2

6. Use according to claim 1, wherein the fatty acid composition is produced from a marine oil.

7. Use according to claim 1, wherein the fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.

8. Use according to claim 1, wherein the fatty acid composition is administered orally to a human or an animal.

9. Use according to claim 1, wherein the treatment is carried out together with a reduced intake of calories for a human or an animal.

10. Use according to claim 1, wherein said fatty acid composition is administered in a daily dosage in the interval 10-40 % of the total lipid content of a daily diet for a human or an animal.

11. Use according to claim 1, wherein said fatty acid composition is administered in an amount providing a daily dosage of 1 g to 15 g of said fatty acid composition, preferably between 2 and 6 g for a human.

12. A method for treatment and/or prevention of obesity, an overweight condition or for controlling body weight reduction and/or prevention of body weight gain, wherein an effective amount of a fatty acid composition comprising (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, is

AMENDED SHEET

3

administered to a human or an animal, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is equal or greater than 1.

5 13. A method according to claim 12, wherein the combination of EPA and DHA are present in the composition in an EPA:DHA ratio from about 1:1 to 1:8, preferably in an EPA:DHA ratio from 1:1 to 1:6.

10 14. A method according to claim 12, wherein the fatty acids in the composition is presented in at least one of esterified form, ethyl ester form, salt form and free acid form, or any combinations thereof.

15 15. A method according to claim 12, wherein the fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.

20 16. A method according to claim 12, wherein at least one of EPA and DHA is obtained from at least one of vegetable, microbial and animal origins.

25 17. A method according to claim 12, wherein at least a part of the EPA and/or DHA is produced from a marine oil, preferably a fish oil.

30 18. A method according to claim 12, wherein the composition is administered orally to a human or an animal.

19. A method according to claim 12, wherein the treatment is carried out together with a reduced intake of calories for the human or an animal.

AMENDED SHEET

20. A method according to claim 12, wherein said fatty acid composition is administered in a daily dosage that corresponds to at least 10 % of the total lipid content
5 of a daily diet for a human or an animal.

21. Use of a fatty acid composition comprising (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-
10 docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, for the production of a food stuff or food supplement for controlling and supporting body weight reduction and/or for prevention of body weight gain, wherein the weight ratio of EPA:DHA in the
15 fatty acid composition is 1:X, where X is equal or greater than 1.

22. Use according to claim 21, wherein the combination of EPA and DHA are present in the composition in an EPA:DHA
20 ratio from about 1:1 to 1:8, preferably in an EPA:DHA ratio from 1:1 to 1:6.

23. Use according to claim 21, wherein the fatty acids in the composition is presented in at least one of
25 esterified form, triglyceride form, ethyl ester form, salt form and free acid form, or any combinations thereof.

24. Use according to claim 21, wherein the fatty acid
30 composition is comprised of a combination of EPA and DHA presented in triglyceride form.

AMENDED SHEET

01-12-2005

5

25. Use according to claim 21, wherein at least one of EPA and DHA is obtained from at least one of vegetable, microbial and animal origins or combinations thereof.

5 26. Use according to claim 21, wherein the at least a part of the EPA and/or DHA is produced from a marine oil, preferably a fish oil.

10 27. Use according to claim 21, wherein the fatty acid composition is produced from a marine oil.

28. Use according to claim 21, wherein the composition is administered orally to a human or an animal.

15 29. Use according to claim 21, wherein the control of body weight, prevention of weight gain and fat reduction is carried out together with a reduced intake of calories for a human or an animal.

20 30. Use according to claim 21, wherein said fatty acid composition is administered in a daily dosage that corresponds to at least 10 % of the total lipid content of a daily diet for a human or an animal.

25 31. Use according to claim 21, wherein the food stuff or food supplement is in form of a gelatine capsule, which capsule is flavoured.

30 32. Use according to claim 21, wherein the fatty acid composition is a liquid or an emulsion, and the food stuff or food supplement being administrated as a beverage.

AMENDED SHEET

6

33. Use according to claim 21, wherein said fatty acid composition comprising DHA or a combination of EPA and DHA is administered in an amount providing a daily dosage of 1 g to 15 g of said fatty acid composition, preferably
5 between 2 and 6 g to a human.

34. A dietary product containing a fatty acid composition comprising (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-
10 4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, for non-medical treatment and/or prevention of obesity, an overweight condition and/or for supporting and
controlling body weight reduction and/or for prevention
15 of body weight gain, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is equal or greater than 1.

35. A dietary product according to claim 34, wherein the
20 main active ingredient is DHA.

36. A dietary product according to claim 34, wherein the dietary product is a weight-watching product or a
slimming product.

25

37. A dietary product according to claim 34, wherein the combination of EPA and DHA are present in the composition in an EPA:DHA ratio from about 1:1 to 1:8, preferably in an EPA:DHA ratio from 1:1 to 1:6.

30

38. A dietary product according to claim 34, wherein at least one of EPA and DHA is obtained from at least one of

AMENDED SHEET

vegetable, microbial and animal origins or combinations thereof.

39. A dietary product according to claim 34, wherein the
5 fatty acid composition is produced from a marine oil,
preferably a fish oil.

40. A dietary product according to claim 34, wherein
intake of the dietary product is combined with a reduced
10 intake of calories for a human and/or together with
physical activity.

41. A dietary product according to claim 34, wherein said
fatty acid composition is administered in a daily dosage
15 that corresponds to at least 10 % of the total lipid
content of a daily diet for a human or an animal.

42. A dietary product according to claim 34, wherein the
dietary product is a bar, snacks or a beverage.

20

43. Use of a fatty acid composition comprising (all-Z
omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or
derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-
docosaheptaenoic acid (DHA), or derivatives thereof, or
25 any combinations thereof, in the manufacture of a dietary
product for prevention of body weight gain and/or for
controlling and supporting weight reduction in a human,
wherein the weight ratio of EPA:DHA in the fatty acid
composition is 1:X, where X is equal or greater than 1.

30

44. A method for supplementing a dietary product
comprising the step of

AMENDED SHEET

8

adding a fatty acid composition comprising (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or
5 any combinations thereof, to the supplement product for prevention of body weight gain and/or for controlling and supporting weight reduction in a human, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is equal or larger than 1.

10

45. A method according to claim 44, wherein the fatty acid composition is presented in liquid form or as an emulsion, being incorporated in the supplement product.

AMENDED SHEET